Cellectis (CLLS) Non-Current Deferred Tax Liability (2022 - 2026)
Cellectis (CLLS) posted quarterly Non-Current Deferred Tax Liability of $118000.0 for Q3 2024, down 25.32% quarter-over-quarter from $158000.0 in Q4 2023.
Powered by 
Analysis
Cellectis (CLLS) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends
Cellectis' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $118000.0 for Q3 2024.
- In Q3 2024, Non-Current Deferred Tax Liability changed N/A year-over-year to $118000.0; the TTM figure through Sep 2024 stood at $118000.0 (changed N/A YoY), while the FY2023 annual figure was $158000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q3 2024 stood at $118000.0, down from $158000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $158000.0 in Q4 2023, with the low at $118000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90.92 Mn |
| Mar 31, 2026 | 93.06 Mn |
| Dec 31, 2025 | 96.80 Mn |
| Sep 30, 2025 | 94.01 Mn |
| Jun 30, 2025 | 113.38 Mn |
| Mar 31, 2025 | 113.30 Mn |
| Dec 31, 2024 | 112.16 Mn |
| Sep 30, 2024 | 118,000.00 |
| Dec 31, 2023 | 158,000.00 |
| Dec 31, 2022 | 59,000.00 |